Age X Therapeutics, Inc. AGE
We take great care to ensure that the data presented and summarized in this overview for AgeX Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGE
View all-
Broadwood Capital Inc New York, NY3MShares$00.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA702KShares$00.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI286KShares$00.01% of portfolio
-
Prescott General Partners LLC Boca Raton, FL185KShares$00.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX145KShares$00.0% of portfolio
-
Geode Capital Management, LLC Boston, MA141KShares$00.0% of portfolio
-
Black Rock Inc. New York, NY124KShares$00.0% of portfolio
-
Strategic Wealth Investment Group, LLC97.4KShares$00.01% of portfolio
-
Creative Planning Overland Park, KS70.7KShares$00.0% of portfolio
-
Northern Trust Corp Chicago, IL31.5KShares$00.0% of portfolio
Latest Institutional Activity in AGE
Top Purchases
Top Sells
About AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Insider Transactions at AGE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2023
|
Juvenescence LTD Director |
SELL
Bona fide gift
|
Direct |
16,447,500
-100.0%
|
-
|
|
Mar 11
2023
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,060
-2.46%
|
$0
$0.59 P/Share
|
|
Mar 11
2023
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+6.77%
|
-
|
|
Dec 11
2022
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-2.64%
|
$0
$0.59 P/Share
|
|
Dec 11
2022
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+7.08%
|
-
|
|
Sep 11
2022
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-2.37%
|
$0
$0.56 P/Share
|
|
Sep 11
2022
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+6.42%
|
-
|
|
Jun 11
2022
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-2.48%
|
$0
$0.77 P/Share
|
|
Jun 11
2022
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+6.7%
|
-
|
|
Mar 11
2022
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,281
-3.07%
|
$0
$0.69 P/Share
|
|
Mar 11
2022
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+6.97%
|
-
|
|
Dec 11
2021
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-2.73%
|
$0
$0.64 P/Share
|
|
Dec 11
2021
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+7.31%
|
-
|
|
Sep 11
2021
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-2.87%
|
$1,081
$1.0 P/Share
|
|
Sep 11
2021
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+7.67%
|
-
|
|
Jun 11
2021
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-3.04%
|
$1,081
$1.53 P/Share
|
|
Jun 11
2021
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+8.08%
|
-
|
|
Mar 11
2021
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,284
-3.81%
|
$2,568
$2.03 P/Share
|
|
Mar 11
2021
|
Michael D West Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+8.48%
|
-
|
|
Dec 11
2020
|
Michael D West Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-3.41%
|
$1,081
$1.69 P/Share
|